Alvotech and Fuji Pharma announce exclusive agreement for commercialisation of Stelara®biosimilar in Japan

Apr 9, 2019

Alvotech and Fuji Pharma announce exclusive agreement for the commercialisation of Stelara® biosimilar in Japan. Alvotech will be responsible for development and supply while Fuji Pharma will receive exclusive rights to commercialise the drug in Japan. This follows Fuji Pharma’s recent US $50 million investment in Alvotech.



Print Page Mail Article